Skip to main content

New MeaningfulUse Rule will likely impact Stage 1 Criteria


Most Health IT folks today are concerned about Meaningful Use for Stage 2, but they should also be concerned about stage 1 as well.  Under new Federal Regulation for meaningful use, it is certainly possible that the definition of stage 1 meaningful use can change.  As the Meaningful Use Standards final rule stated:
The stages of criteria of meaningful use and how they are demonstrated are described further in this final rule and will be updated in subsequent rulemaking to reflect advances in HIT products and infrastructure. We note that such future rulemaking might also include updates to the Stage 1 criteria.
The real question for many is what that will mean for vendors implementing products, and providers attesting to meaningful use at a particular stage.  For vendors, it is very clear that EHR products will need to be certified against the new criteria as soon as possible, because again, according to both the final rule for temporary certification and for permanent certification:
Regardless of the year and meaningful use stage at which an eligible professional or eligible hospital enters the Medicare or Medicaid EHR Incentive Program, the Certified EHR Technology that they would need to use would have to include the capabilities necessary to meet the most current certification criteria adopted by the Secretary at 45 CFR 170 subpart C. 
When Stage 2 becomes effective (anticipated for 2014), providers will need to upgrade to EHR technology that is certified to that criteria, regardless of whether they are attesting to Stage 1 or Stage 2 of Meaningful Use criteria.  The new incentives rule will contain criteria defined for those organizations who are a “Stage 1” Meaningful User and for those who are a “Stage 2” Meaningful User.  Stage 2 users will have more criteria to attest to, and for those capabilities already existing in stage 1, a higher degree of use of those capabilities (e.g., A higher percentage of orders performed electronically at stage 2 than stage 1).  Regardless of whether they are at Stage 1 or Stage 2, both kinds of organizations will have to use EHR technology that has been certified to support the Stage 2 criteria.  

The table below shows the current Stage 1 standards and the stage 2 standards that I’m currently projecting for the new Meaningful Use Standards rule.


Stage 1
Stage 2

January 2011 – December 2013
January 2014 – ?
Purpose
Standard
Implementation Guide
Standard
Implementation Guide
Generating a Clinical Summary
CCD 1.0
HITSP C32 V2.5
CDA R2.0
CCD 1.1
(Stage 1)
CCR


CDA Consolidation Guide (Stage 2)
Viewing a Clinical Summary
Both CCR and HITSP C32 V2.5
CDA Consolidation Guide, CCR and HITSP C32 V2.5
Immunizations
HL7 V2.3.1
CDC 2.3.1 Guide


HL7 V2.5.1
CDC 2.5.1 Guide
HL7 2.5.1
CDC 2.5.1 Guide
Public Health Lab Reporting
HL7 V2.5.1
ELR Guide

ELR Guide and/or updated LRI Guide
Disease Surveillance
HL7 V2.3.1
No Guide Selected


HL7 V2.5.1
HL7 V2.5.1
PHIN Guide

The new certification criteria for Stage 1 and Stage 2 will almost assuredly require use of new standards, and some standards previously acceptable will be dropped.  The biggest challenge for many will be the change from CCR/HITSP C32 V2.5 to CDA® and the CDA Consolidation Guide, and that is what this post will focus upon.    The key question is how systems conforming to the new standards will address the issue of the legacy data stored using either CCR or the HITSP C32 2.5.  

Fortunately, ONC cleverly created two separate criteria for the clinical summary.  The first was generating (and subsequently transmitting) an electronic summary.  ONC allowed two formats for that capability: CCR or the HITSP C32 2.5, of which a provider need choose only one (but could support both).  However, all systems must support viewing both (and need not do any more than that).

In order to support viewing of legacy documents, I fully expect that the new certification criteria will require certified systems to support viewing of legacy content.  I also expect it to support viewing of any document found in the CDA Consolidation guide.  With the exception of the Unstructured Document, viewing is not a challenge.  IHE implementers have learned over the years to sign up for the “Content Consumer” actor for all PCC Profiles of the HL7 CDA if they can support content consumer for ANY document because you get it nearly for free.  Most implementations transform CDA to HTML or XHTML and display the results.  A good stylesheet handles all bontent equally well.  Thus, it is reasonable to ask these systems to support viewing of any CDA based content under the new certification criteria.  If you can view one kind of CDA document using an XSL stylesheet, you should be able to view many.  There are numerous sources of code for CDA stylesheets freely available. 

The Unstructured Document in the CDA Consolidation guide needs more work for viewing but there are plenty of viewing technologies available to support its requirements as well.  There's another whole post that I will devote to that topic.

On the creation side, I expect that systems must be able to create content using the CDA Consolidation Guide.  A stage 1 meaningful user might only be required to generated CCD 1.1 documents, but a Stage 2 user might be required to support not just CCD 1.1 but could be permitted or even required to generate other document types in the CDA Consolidation Guide (e.g., discharge summary).

Where backwards compatibility becomes a problem for organizations that are exceeding the meaningful use requirements, such as the Beacon programs.  Those organizations have been working with CCD 1.0 and will now need to support CCD 1.1.  That is one of the penalties of getting out in front.  The key for those programs will be adapting their technology that uses the HITSP C32 V2.5 to use CCD 1.1.  It may be a PITA, but this is really not a hard challenge. 

Given the origins of CCD 1.1, it should certainly be feasible to transform from CCD 1.0 to CCD 1.1 automatically.  While there are some incompatibilities between the two versions, a valid HITSP C32 Version 2.5 will almost certainly transform into a valid CCD 1.1 for the purpose of importing, reconciliation, et cetera.  The transition to CCD 1.1 even prior to its adoption as a certification requirement could be done within the context of the single system that makes use of it, enabling innovators to take advantage of it before it becomes a requirement.

Shortly HL7 will be releasing the latest CDA Consolidation template database, and the Model Driven Health Tools project will be releasing a version which includes the CDA Consolidation rules.  Those two model driven tools will provide engineers (including me) with a lot more information than we’ve ever had previously to make the transition to the new format easier.

-- Keith

Comments

Popular posts from this blog

clip on magnetic sunglasses visit here

Save with prescription glasses and sunglasses. Prescription eyeglasses with magnetic clip on sunglasses. A wide selection of colors and styles for every budget! -GlassesPoint. Prescription eyeglasses with magnetic clip on sunglasses. A wide selection of colors and styles for every budget! Free magnetic clip on with every pair of glasses.  The operator should contact lens Plano glasses a few days of Sun and Rx on the other person. Many people choose single vision lenses, designed for a specific use, such as prescription sunglasses. Clip-ons magnetic magnetic clip ons often come with their prescription glasses frames. Prescription glasses Goggles4u dollars from 29.99 with free shipping. Takumi neodium magnet glass features recipes that are light, strong and in. The combination of some normal prescription glasses and a pair of polarized glasses that glare-resistant to outdoor activities. clip on magnetic sunglasses visit here

The Tragedy of Underfunded Mental Health Care

Today’s Managing Health Care Costs Indicator is   19,900 The NY Times  on Friday had a deeply disturbing article on a murder that stunned the mental health community here in Massachusetts.    A long-term schizophrenic man, off his medicine and spiraling into incoherence, killed a young female counselor who was the sole worker at a group home in a Boston suburb.   His mother, who works at a Boston teaching hospital, was frantic with worry as her adult son, who had been arrested for assault multiple times, was becoming more psychotic.    It was hard for her to get anyone’s attention. The counselor was the first in her family to get a college degree, and had just decided to go to nursing school.    Now she’s dead – and her family had trouble scraping together the resources for a burial.   The schizophrenic will be imprisoned for the rest of his life – which ironically could be the best chance for him to get appropriate medical care. Both...

How a Well-Intended FDA Policy on Colchicine is Harming Patients

The road to hell is paved with good intentions. The FDA has reaffirmed the truth of this aphorism with its policy about Colchicine. Here's the story: I recently spoke with a friend who has a family member suffering from Familial Mediterranean Fever (FMF), an auto-inflammatory disorder, most commonly seen in eastern Mediterranean populations. The condition is characterized by recurrent painful inflammation of the abdomen, chest and joints, accompanied by fever. FMF is associated with mutation of a gene on chromosome 16 involved with regulating Pyrin, a protein that is part of the inflammatory response. There is no specific test for the disease. Diagnosis is made on the basis of symptoms, family history, and ruling out other conditions. Since the 1960s, Colchicine, a plant extract first used for treatment of gout two thousand years ago, has been used for treating FMF. As an ancient treatment widely used prior to formation of the FDA, Colchicine did not require FDA approval as a new ...